Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul 31;12(7):1636-1642.
doi: 10.21037/tlcr-23-245. Epub 2023 May 31.

Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail

Ayse Ece Cali Daylan  1 , Balazs Halmos  1
Affiliations
Editorial

Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail

Ayse Ece Cali Daylan et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Immunotherapy; metastatic; non-small cell lung cancer (NSCLC); pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-245/coif). BH has grants or contracts from Boehringer Ingelheim, Astra Zeneca, Merck, BMS, Advaxis, Amgen, AbbVie, Daiichi, Pfizer, GSK, Beigene, Janssen, Numab and Arrivent and is on monitoring/advisory boards of Astra Zeneca, Boehringer Ingelheim, Apollomics, Janssen, Takeda, Merck, BMS, Genentech, Pfizer, Eli-Lilly, TPT and Arcus. The other author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Suggested treatment algorithm for stage IV NSCLC. †, ± bevacizumab for nonsquamous NSCLC if IMpower150 regimen is opted for; ‡, not FDA approved. NSCLC, non-small cell lung cancer; PD-L1, programmed cell death ligand 1; TPS, tumor proportion score; PD-1, programmed cell death protein 1; ChT, chemotherapy; inh, inhibitor; CTLA-4, cytotoxic T lymphocyte associated antigen 4; FDA, Food and Drug Administration.
See this image and copyright information in PMC

Comment on

References

    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64. 10.1038/nrc3239 - DOI - PMC - PubMed
    1. Hodi FS, Chiarion-Sileni V, Lewis KD, et al. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. J Clin Oncol 2022;40:abstr 9522.
    1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2019;381:1535-46. 10.1056/NEJMoa1910836 - DOI - PubMed
    1. André T, Lonardi S, Wong KYM, et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol 2022;33:1052-60. 10.1016/j.annonc.2022.06.008 - DOI - PubMed
    1. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51. 10.1200/JCO.2007.15.0375 - DOI - PubMed